Colorectal Adenocarcinoma

P1/2, N=111, Active, not recruiting, Suzhou Transcenta Therapeutics Co., Ltd. | Trial completion date: Aug 2025 --> Dec 2026 | Trial primary completion date: May 2025 --> Jun 2026

P3, N=272, Not yet recruiting, UNICANCER

Pulmonary enteric adenocarcinoma (PEAC), also known as adenocarcinoma-enteric type of the lung, is a rare variant of non-small cell lung cancer (NSCLC) that shows similar morphological and immunohistochemical (IHC) features to colorectal adenocarcinoma and necessitates gastroenteroscopy to exclude enteric-origin lesions...However, their molecular features and therapeutic biomarkers are still unexplored, and their diagnosis and treatment remain difficult. Thus, systematic review and combined analysis data were obtained from previously published literature.

EBF1 presented a promoter hypermethylation pattern in COAD cell lines, in which its expression was restored upon treatment of the methylation inhibitor 5-azacytidine. In conclusion, this study highlights that the hypermethylation of EBF1 leads to transcription activation of DEPDC1B, which promotes cell cycle progression, EMT, and malignant progression in COAD. Restoring EBF1 levels or suppressing DEPDC1B expression may be promising strategies for COAD management.

P1/2, N=86, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Dec 2025 --> Mar 2026

P3, N=477, Recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Aug 2029 --> Mar 2029

Histopathological evaluation may aid risk stratification alongside KRAS status. Prognostic assessment in clinical settings should take both TNM staging and KRAS status into account.

Low CDX2 expression is linked to aggressive pathological features and advanced tumor stage in CRC, highlighting its clinicopathological associations. Semi-quantitative evaluation of CDX2 using both staining ratio and intensity provides a more informative assessment that may aid risk stratification and guide clinical decision-making in CRC patients.

Bladder cancer, particularly in its advanced and cisplatin-resistant forms, poses a significant clinical challenge due to limited therapeutic options...Our results indicate that CST dually inhibits CDK1 and CDC5L and synergizes with the MEK1 inhibitor by suppressing feedback-driven resistance pathways. These findings support the CST + NB combination as a novel multi-target therapeutic strategy with potent activity against bladder cancer and rectal adenocarcinoma.

High TGF-β1 expression in CLO is associated with poor prognosis and an immunosuppressive microenvironment.

P1/2, N=474, Recruiting, A2 Biotherapeutics Inc. | N=230 --> 474

The case emphasizes the importance of correlating clinical, histopathological and radiological findings. Rescreening for malignancy may be prudent in recurrent primary Paget disease.